Alzheimer’s Blood Test Identifies Cognitive Impairment with High Accuracy
New research finds that the PrecivityAD2 blood test can identify brain amyloid status with values that approximate those of PET imaging.
New research finds that the PrecivityAD2 blood test can identify brain amyloid status with values that approximate those of PET imaging.
BrainSee harnesses Darmiyan's patented core proprietary technology, powered by advanced whole-brain image analysis and medical AI.
Resonant published research revealing a blood biomarker of neurodegeneration that achieved 100% accuracy in identifying Alzheimer's patients.
Researchers confirmed the usefulness of NfL blood levels to predict the likelihood of progression of neurodegeneration in Alzheimer’s.
Read MoreA new blood test shows promise as an Alzheimer’s biomarker, and when used in a two-step workflow high accuracy to find brain amyloidosis.
Read MoreResearchers identified a way with a fitness tracker to assess brain activity in sleep that occurs in the earliest stages of Alzheimer’s.
Read MoreMedical director Zaldy Tan, MD, MPH, answers questions about the Alzheimer’s blood test, as well as similar tests that are in development.
Read MoreC2N Diagnostics, has released the PrecivityAD2 blood test, that meets the standard of care with PET scans and cerebrospinal fluid tests.
Read MoreC2N Diagnostics says new research affirms the clinical utility of its PrecivityAD blood test to help diagnose Alzheimer’s.
Read MoreQuest announced the availability a blood test for consumer purchase that helps assess the potential risk of developing Alzheimer’s disease.
Read MoreLow spinal fluid levels of a protein linked to learning and memory in mice may serve as an early predictor of mild cognitive impairment.
Read MoreA new discovery will help scientists understand the mechanisms underlying Alzheimer’s and could serve as a marker for better diagnostics.
Read MoreA simple, finger prick blood test shows promise in the ability to detect Alzheimer’s disease, according to new research.
Read MoreApproximately 80% of older adults haven’t had a cognitive test in the past year to look for signs of Alzheimer’s or other types of dementia.
Read MoreA new study reveals the possibility of detecting Lewy body disease early, prior to the onset of noticeable symptoms, via a spinal fluid test.
Read MoreThis partnership aims to address the global unmet clinical need for blood-based Alzheimer’s Disease diagnostics.
Read MoreScientists have identified a form of tau that could serve as a biomarker to track Alzheimer’s progression.
Read MoreThe ImmunoSEIRA sensor enables the detection and identification of misfolded protein biomarkers associated with neurodegenerative diseases.
Read More